CR vs REGN · P/E 38, rev $2.13B vs P/E 14, rev $14.34B
Crane Company (CR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Crane Company (CR) is a specialty industrial machinery company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CR revenue for 2024-12-31 was $2.13B. Net income was $81.0M. CR currently screens at market cap $12.08B and trailing P/E 38.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CR currently screens at market cap $12.08B and trailing P/E 38.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CR and REGN stock pages for the full models.
Not investment advice.